LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linifanib | 1.11 | uM | LJP6 | 2 | J09 | 72 | hr | 1476 | 4277 | 3694 | 1.1578 | 1.2629 |
| SK-BR-3 | Linifanib | 1.11 | uM | LJP6 | 3 | J09 | 72 | hr | 1476 | 4121 | 3694 | 1.1156 | 1.1926 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 1 | O21 | 72 | hr | 1476 | 2697 | 3694 | 0.7301 | 0.5503 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 2 | O21 | 72 | hr | 1476 | 3190 | 3694 | 0.8636 | 0.7727 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 3 | O21 | 72 | hr | 1476 | 2877 | 3694 | 0.7788 | 0.6315 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 1 | C21 | 72 | hr | 1476 | 1554 | 3694 | 0.4207 | 0.0349 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 2 | C21 | 72 | hr | 1476 | 1359 | 3694 | 0.3679 | -0.0531 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 3 | C21 | 72 | hr | 1476 | 1577 | 3694 | 0.4269 | 0.0452 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 1 | C21 | 72 | hr | 1476 | 1292 | 3694 | 0.3498 | -0.0833 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 2 | C21 | 72 | hr | 1476 | 1411 | 3694 | 0.3820 | -0.0296 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 3 | C21 | 72 | hr | 1476 | 1238 | 3694 | 0.3351 | -0.1077 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 1 | F03 | 72 | hr | 1476 | 2401 | 3694 | 0.6500 | 0.4168 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 2 | F03 | 72 | hr | 1476 | 2463 | 3694 | 0.6668 | 0.4448 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 3 | F03 | 72 | hr | 1476 | 2474 | 3694 | 0.6697 | 0.4498 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 1 | A15 | 72 | hr | 1476 | 1527 | 3694 | 0.4134 | 0.0227 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 2 | A15 | 72 | hr | 1476 | 1368 | 3694 | 0.3703 | -0.0490 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 3 | A15 | 72 | hr | 1476 | 1445 | 3694 | 0.3912 | -0.0143 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 1 | N15 | 72 | hr | 1476 | 3927 | 3694 | 1.0631 | 1.1051 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 2 | N15 | 72 | hr | 1476 | 3871 | 3694 | 1.0479 | 1.0798 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 3 | N15 | 72 | hr | 1476 | 4029 | 3694 | 1.0907 | 1.1511 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 1 | H03 | 72 | hr | 1476 | 3146 | 3694 | 0.8516 | 0.7528 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 2 | H03 | 72 | hr | 1476 | 3135 | 3694 | 0.8487 | 0.7479 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 3 | H03 | 72 | hr | 1476 | 3324 | 3694 | 0.8998 | 0.8331 |
| SK-BR-3 | NU7441 | 1.11 | uM | LJP5 | 1 | C09 | 72 | hr | 1476 | 2835 | 3694 | 0.7675 | 0.6126 |
| SK-BR-3 | NU7441 | 1.11 | uM | LJP5 | 2 | C09 | 72 | hr | 1476 | 2851 | 3694 | 0.7718 | 0.6198 |